Early short-term antiretroviral treatment may benefit HIV-positive babies

08/21/2013 | HealthDay News

Researchers monitored 377 HIV-positive babies for five years and found that those who completed the immediate 96-week antiretroviral treatment were able to avoid restarting the therapy for an average of 70 weeks. Waiting for symptoms to emerge before getting the treatment was linked to substantially higher rates of deaths and hospital admissions as well as greater medical costs than the immediate, temporary treatment. The findings appear in The Lancet.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA